TWD 57.2
(-5.61%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -261.83 Million TWD | 1.36% |
2022 | -265.45 Million TWD | -121.3% |
2021 | -119.95 Million TWD | 7.11% |
2020 | -129.12 Million TWD | 13.45% |
2019 | -149.19 Million TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -48.66 Million TWD | -26.77% |
2024 Q1 | -42.72 Million TWD | 24.7% |
2023 Q1 | -56.29 Million TWD | -23.3% |
2023 Q4 | -56.74 Million TWD | -25.81% |
2023 Q3 | -45.09 Million TWD | 53.26% |
2023 Q2 | -96.49 Million TWD | -71.4% |
2022 Q4 | -45.65 Million TWD | 0.0% |
2022 FY | -265.45 Million TWD | -121.3% |
2021 FY | -119.95 Million TWD | 7.11% |
2020 FY | -129.12 Million TWD | 13.45% |
2019 FY | -149.19 Million TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Apex Biotechnology Corp. | 141.71 Million TWD | 284.762% |
Sinphar Pharmaceutical Co.,Ltd. | 286.05 Million TWD | 191.533% |
Panion & Bf Biotech Inc. | 156.82 Million TWD | 266.957% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 280.8 Million TWD | 193.244% |
GenMont Biotech Incorporation | 6.98 Million TWD | 3846.952% |
Abnova (Taiwan) Corporation | 47.19 Million TWD | 654.81% |
Adimmune Corporation | -722.74 Million TWD | 63.772% |
Tanvex BioPharma, Inc. | -2.1 Billion TWD | 87.536% |
Polaris Group | -1.84 Billion TWD | 85.824% |
UnicoCell Biomed Co., Ltd. | -96.28 Million TWD | -171.954% |
PELL Bio-Med Technology Co. Ltd. | -411.24 Million TWD | 36.331% |